Physician profile
Michael Ko
NPI 1922088111
$111,441.27
in general payments reported to CMS, 2019-2025
10 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $21K · 2021: $23K · 2022: $21K · 2023: $10K · 2024: $404 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,384 · Food and Beverage: $1,267 · Consulting Fee: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,384.00 |
| Food and Beverage | $1,267.19 |
| Consulting Fee | $252.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $62,695.28 | 2019-2025 | Tysabri, Tysabri, Vumerity |
| Emd Serono, INC. | $47,818.04 | 2019-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $328.71 | 2023-2025 | |
| Genentech USA, INC. | $241.61 | 2019-2024 | Ocrevus, Enspryng |
| Celgene Corporation | $162.42 | 2022-2024 | Zeposia |
| Lundbeck LLC | $77.07 | 2025 | Vyepti |
| Abbvie INC. | $54.04 | 2023-2025 | |
| Ucb, INC. | $27.64 | 2024 | Fintepla |
| Ani Pharmaceuticals, INC. | $22.87 | 2025 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.